Priority will be given to unvaccinated or undervaccinated, which means those not up to date include those who are not vaccinated, have not completed their initial series i.e. 2 doses of Pfizer/Moderna or 1 dose of J & J. If past 5 months from primary series of vaccination with Pfizer or Moderna then should have a booster or considered as not up to date. Those with J & J, should have booster 2 months after primary vaccination to be considered up to date.
FDA Emergency Use Authorization only allows for one MAB currently which is Bebtelovimab.
Bebtelovimab (LY-CoV1404; LY3853113) is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 that maintains binding and neutralizing activity across currently known and reported variants of concern, including Omicron and BA.2. Bebtelovimab is being studied for the treatment of mild-to-moderate COVID-19 both as a monotherapy and together with other mAbs. Lilly has licensed and developed bebtelovimab after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.Bebtelovimab is not authorized for use in patients who:
Monoclonal antibodies are developed in a lab and function similarly to your body’s inherent naturally occurring antibodies. Monoclonal antibodies are administered intravenously to high-risk COVID-19 patients diagnosed with the early stages of the disease. Generally, the infusion decreases risk of progression of COVID-19 from mild and moderate disease to severe disease by a 3-4X relative risk reduction.
This treatment is generally used to decrease viral loads and reduce symptom severity in high-risk COVID-19 patients. Monoclonal antibodies can detect and target the spike protein found on the outer part of the COVID-19 virus. This reduces the virus’s ability to attach itself and enter human cells. Generally, it has been proven to boost our immune system and help it fight off the novel coronavirus. It also helps decrease the risk of being hospitalized.Book MAB Appointment!
Per CDC, if you have been treated with a monoclonal antibody infusion, you should not get a COVID-19 vaccination within 90 days of your infusion.
Please refer to our criteria section to see if you are eligible. If you are unsure, you may fill out our form and our team will assess your eligibility.
Side effects are rare but may include infusion reactions such as nausea, vomiting, diarrhea, fever, headache, chills, wheezing or coughing, decreased blood pressure, skin swelling, rashes, throat irritation, muscle pain/ache, itching, weakness, and dizziness. Inform your doctor immediately if you feel any of these symptoms after the infusion.
Whether or not you have received monoclonal antibody therapy, you need to be isolated if you have tested positive for COVID-19.
As of January 20th, 2022 – Blue Cross PPO and Medicare are providing coverage. However, please check with your insurance provider to see if you can receive the infusion at no cost to you.